Atara Biotherapeutics, Inc. (ATRA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-05-11

Key Insights

  • EcoR1 Capital and affiliated entities purchased 507,407 shares of ATRA on 05/07/2026 at a weighted average price of $9.35, demonstrating continued insider confidence in the company at current valuation levels.
  • The Qualified Fund's total position increased to 1,552,000 shares following this transaction, representing a significant long-term commitment from a major institutional investor with board representation.
  • This purchase was executed at prices ranging from $8.85 to $9.39, suggesting accumulation during a stable price period rather than opportunistic buying at depressed levels.
  • EcoR1 Capital's status as both a Director and 10% Owner provides strong alignment of interests with public shareholders, though the disclaimer of group membership indicates separate investment decision-making.
Filing tone (AI): Positive
View Original Filing →
Current Report Filed: 2026-05-01

Key Insights

  • Atara has fallen below Nasdaq's $50 million minimum market value requirement and received a delisting notice, indicating severe financial distress and shareholder value deterioration.
  • The company has 180 calendar days until October 27, 2026 to regain compliance by achieving a $50M+ market value for 10 consecutive business days, but faces uncertainty in achieving this milestone.
  • Management has acknowledged potential options including transfer to Nasdaq Capital Market, but provided no concrete plan or timeline for resolving the listing violation, suggesting limited near-term remediation strategies.
  • The filing contains forward-looking statements with substantial risk disclaimers and references to undisclosed risk factors in prior 10-K filings, warning investors of material uncertainties beyond the delisting issue.
Filing tone (AI): Negative
View Original Filing →
Insider Trading Filed: 2026-03-19

Key Insights

  • Panacea Innovation Ltd, a 10% owner of Atara Biotherapeutics, Inc. (ATRA), has exercised 259,163 warrants for the company's common stock at an exercise price of $0.0001 per share.
  • James Huang, who is the sole owner of Panacea Innovation Ltd, is also a director of Atara Biotherapeutics and may be deemed to share beneficial ownership of the securities held by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P.
  • The insider transactions indicate Panacea Innovation Ltd's continued confidence in Atara Biotherapeutics, as the entity has increased its stake in the company through the warrant exercise.
Filing tone (AI): Positive
View Original Filing →
Current Report Filed: 2026-03-16

Key Insights

  • Atara Biotherapeutics announced its financial results for Q4 and full-year 2025, indicating the company's operational progress during that period.
  • The press release accompanying the 8-K filing provides details on the company's financial performance, which investors will want to review carefully.
  • The 8-K filing itself does not contain any major announcements or material events, but the accompanying financial information is still significant for understanding the company's current state.
Filing tone (AI): Neutral
View Original Filing →
Annual Report Filed: 2026-03-16

Key Insights

  • Atara Biotherapeutics' research and development expenses increased significantly in 2025, indicating a focus on advancing its pipeline of novel therapies.
  • The company reported an increase in commercial revenue in 2024, suggesting progress in commercializing its products.
  • Atara has been active in raising additional capital through various financing activities, including public offerings and at-the-market offerings, to support its ongoing operations and development efforts.
Filing tone (AI): Positive
View Original Filing →
Current Report Filed: 2026-03-12

Key Insights

  • Atara Biotherapeutics has scheduled a Type A meeting with the FDA to discuss the Complete Response Letter for the EBVALLOâ„¢ Biologics License Application, indicating potential progress in addressing the regulatory concerns.
  • The company is working closely with its partner, Pierre Fabre Pharmaceuticals, to collaborate with the FDA and resubmit the BLA with additional efficacy data collected since the original submission.
  • Atara is confident in the potential of its allogeneic Epstein-Barr virus (EBV) T-cell platform and is committed to bringing tabelecleucel (tab-cel) to market for patients with EBV+ PTLD.
Filing tone (AI): Positive
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Panacea Innovation Ltd, a 10% owner, sold 80,554 shares of Atara Biotherapeutics, Inc. (ATRA) at an average price of $6.0707 per share. This suggests some reduction in their ownership stake in the company.
  • James Huang, the sole owner of Panacea Innovation Ltd, is also a director and 10% owner of Atara Biotherapeutics, indicating strong ties between the reporting persons and the issuer.
  • The filing also shows that Panacea Opportunity Fund I, L.P., another entity associated with the reporting persons, owns an additional 48,736 shares of Atara Biotherapeutics.
Filing tone (AI): Neutral
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Atara Biotherapeutics received a Complete Response Letter from the FDA for its EBVALLO (tabelecleucel) Biologics License Application, indicating further regulatory review is required before approval.
  • The company's cash, cash equivalents and short-term investments position as of December 31, 2025 was preliminarily disclosed, which provides insight into its current financial condition.
  • Investors should monitor the company's progress with EBVALLO and the potential impact of the regulatory setback on its business and outlook.
Filing tone (AI): Negative
View Original Filing →
Current Report Filed: 2026-01-02

Key Insights

  • Atara Biotherapeutics has reached a new agreement with Pierre Fabre Medicament to reduce milestone payments related to the approval of tab-cel by the FDA, but gain a potential $15 million commercial milestone payment.
  • The reduction in milestone payments may provide near-term financial benefits for Atara, but the company is trading off potential upside from tab-cel's approval.
  • The amended agreement suggests Atara and Pierre Fabre are working to optimize the commercial partnership for tab-cel, though the long-term impact on the company's financials is unclear.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Atara Biotherapeutics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.